Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance

npj Biofilms and Microbiomes

Volumn 3, Issue 1, 2017, Pages

  Beaudoin, T ^a   Yau, Y C W ^b   Stapleton, P J ^b   Gong, Y ^c   Wang, P W ^c   Guttman, D S ^d   Waters, V ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85036570335     PISSN: None     EISSN: 20555008     Source Type: Journal    
DOI: 10.1038/s41522-017-0035-0     Document Type: Article

References (37)

1. O'Neill, J. Antimicrobial resistance: tackling a crisis for health and wealth of nations. Rev. Antimicrob. Resistance 16 (2014).
2. Doern, G. & Breacher, S. The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests. J. Clin. Microbiol. 49, S11 (2011).
3. Hauser, A. R., Jain, M., Bar-Meir, M. & McColley, S. A. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24, 29-70 (2011).
4. Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318-1322 (1999).
5. Hall-Stoodley, L., Costerton, J. W. & Stoodley, P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2, 95-108 (2004).
6. Cystic Fibrosis Foundation. Patient registry: annual data report 2014. Cystic Fibrosis Foundation, Bethesda, MD. (2015).
7. Wolter, D. J. et al. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin. Infect. Dis. 57, 384-391 (2013).
8. Schelstraete, P., Haerynck, F., Van daele, S., Deseyne, S. & De Baets, F. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa. J. Cyst. Fibros. 12, 1-8 (2013).
9. Douglas, T. A. et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur. Respir. J. 33, 305-311 (2009).
10. Mayer-Hamblett, N. et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr. Pulmonol. 47, 125-134 (2012).
11. Mayer-Hamblett, N. et al. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin. Infect. Dis. 59, 624-631 (2014).
12. Vidya, P. et al. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. (2015).
13. Blanchard, A. et al. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J. Cystic Fibrosis 16, 395-400 (2017). In press.
14. Vorregaard, M. Comstat2-a modern 3D image analysis environment for biofilms, in Informatics and Mathematical Modelling. (2008).
15. Heydorn, A. et al. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology 146(Pt 10), 2395-2407 (2000).
16. Konstan, M. W. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J. Cyst. Fibros. 10, 54-61 (2011).
17. Armbruster, C. R. et al. Staphylococcus aureus protein A mediates interspecies interactions at the cell surface of Pseudomonas aeruginosa. MBio 7, https://doi.org/10.1128/mBio.00538-16 (2016).
18. Tran, V. B., Fleiszig, S. M. J., Evans, D. J. & Radke, C. J. Dynamics of flagellum- and pilus-mediated association of Pseudomonas aeruginosa with contact lens surfaces. Appl. Environ. Microbiol. 77, 3644-3652 (2011).
19. Petrova, O. E. & Sauer, K. Sticky situations: key components that control bacterial surface attachment. J. Bacteriol. 194, 2413-2425 (2012).
20. Overhage, J., Schemionek, M., Webb, J. S. & Rehm, B. H. Expression of the psl operon in Pseudomonas aeruginosa PAO1 biofilms: PslA performs an essential function in biofilm formation. Appl. Environ. Microbiol. 71, 4407-4413 (2005).
21. Jackson, K. D., Starkey, M., Kremer, S., Parsek, M. R. & Wozniak, D. J. Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J. Bacteriol. 186, 4466-4475 (2004).
22. Ma, L., Lu, H., Sprinkle, A., Parsek, M. R. & Wozniak, D. J. Pseudomonas aeruginosa Psl is a galactose- and mannose-rich exopolysaccharide. J. Bacteriol. 189, 8353-8356 (2007).
23. Byrd, M. S. et al. Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production. Mol. Microbiol. 73, 622-638 (2009).
24. Yang, L. et al. Distinct roles of extracellular polymeric substances in Pseudomonas aeruginosa biofilm development. Environ. Microbiol. 13, 1705-1717 (2011).
25. Chew, S. C. et al. Dynamic remodeling of microbial biofilms by functionally distinct exopolysaccharides. MBio 5, e01536-14 (2014).
26. Ma, L. et al. Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog. 5, e1000354 (2009).
27. Xiao, J. et al. The exopolysaccharide matrix modulates the interaction between 3D architecture and virulence of a mixed-species oral biofilm. PLoS Pathog. 8, e1002623 (2012).
28. Billings, N. et al. The extracellular matrix component Psl provides fast-acting antibiotic defense in Pseudomonas aeruginosa biofilms. PLoS Pathog. 9, e1003526 (2013).
29. Merino, N. et al. Protein A-mediated multicellular behavior in Staphylococcus aureus. J. Bacteriol. 191, 832-843 (2009).
30. Pernet, E. et al. Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nat. Commun. 5, 5105 (2014).
31. Staudinger, B. J. et al. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 189, 812-824 (2014).
32. Caceres, S. M. et al. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob. Agents Chemother. 58, 6851-6860 (2014).
33. Borlee, B. R. et al. Pseudomonas aeruginosa uses a cyclic-di-GMP-regulated adhesin to reinforce the biofilm extracellular matrix. Mol. Microbiol. 75, 827-842 (2010).
34. Beaudoin, T., Kennedy, S., Yau, Y. & Waters, V. Visualizing the effects of sputum on biofilm development using a chambered coverglass model. J. Vis. Exp. https://doi.org/10.3791/54819 (2016).
35. Tom, S. K., Yau, Y. C., Beaudoin, T., LiPuma, J. J. & Waters, V. Effect of high-dose antimicrobials on biofilm growth of Achromobacter species isolated from cystic fibrosis patients. Antimicrob. Agents Chemother. 60, 650-652 (2015).
36. Kennedy, S. et al. Activity of tobramycin against cystic fibrosis isolates of burkholderia cepacia complex grown as biofilms. Antimicrob. Agents Chemother. 60, 348-355 (2015).
37. Bales, P. M., Renke, E. M., May, S. L., Shen, Y. & Nelson, D. C. Purification and characterization of biofilm-associated eps exopolysaccharides from eskape organisms and other pathogens. PLoS ONE 8, e67950 (2013).